Clinical Trial Update: An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer [Phase 1]

View source ↗

Summary

An open-label Phase 1 study evaluating the pharmacokinetics and pharmacodynamics of repeat escalating oral doses of the AKT inhibitor GSK2141795 in ovarian canc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• GSK2141795 (GSK2141795)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Solid Tumours | Phase 1 | Status: COMPLETED